Rucaparib and olaparib for the treatment of prostate cancer: A clinician's guide to choice of therapy

Abstract

Objective

This review will provide an overview of the use rucaparib and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC) with the goal to assist the clinician's decision-making process when considering these agents for an individual patient.

Data Sources

Searches were conducted in PubMed, relevant meeting abstracts, clinicaltrials.gov, and United States Food and Drug Administration (FDA) documents to identify literature published through July 1, 2021, related to use of rucaparib and olaparib for treatment of prostate cancer.

Data Summary

In May 2020, the FDA approved rucaparib and olaparib for treatment of mCRPC that is homologous recombination repair (HRR)-deficient. Both agents are approved for previously-treated patients, but there are notable differences in strength of evidence, outcomes studied, required HRR alteration, and required prior therapies. In patients who qualify for therapy, additional factors that may help guide choice of PARP inhibitor include baseline organ function, drug interaction potential, toxicity profiles, and financial factors.

Conclusions

Rucaparib and olaparib have the potential to improve outcomes for patients with HRR-deficient mCRPC. Differences in strength of evidence and patient- and drug-specific characteristics will assist the clinician when choosing between agents.

Keywords

Prostate cancer PARP inhibitor rucaparib olaparib

Get full access to this article

View all access options for this article.

References

American Cancer Society. Cancer Statistics Center, http://cancerstatisticscenter.cancer.org (2021, accessed 26 March 2021).

U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication (2017, accessed 7 July 2021).

Latham

Srinivasan

Kemel

, et al. Microsatellite instability is associated with the presence of lynch syndrome pan-cancer. J Clin Oncol 2019; 37: 286–295.

Abida

Cheng

Armenia

, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol 2019; 5: 471–478.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer, version 2.2021, http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (2021, accessed 30 June 2021).

Vitrakvi (larotrectinib). [Package insert on the internet]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc., 2021 [revised 2021 March, cited 2021 Jun 29]. Available from: http://labeling.bayerhealthcare.com/html/products/pi/vitrakvi_PI.pdf.

Rozlytrek (entrectinib). [Package insert on the internet]. South San Francisco, CA: Genentech USA, Inc., 2019 [revised 2019 Aug, cited 2021 Jun 29]. Available from: https://www.gene.com/download/pdf/rozlytrek_prescribing.pdf.

Moasser

. Neoplasia. In: Hammer

McPhee

(eds) Pathophysiology of disease: an Introduction to clinical medicine. 8e. New York, NY: McGraw-Hill Education, 2019.

Castro

Goh

Olmos

, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013; 31: 1748–1757.

10.

Wei

, et al. Prognostic value of germline DNA repair gene mutations in De Novo metastatic and castration-sensitive prostate cancer. Oncologist 2020; 25: e1042–e1e50.

11.

Page

Bancroft

Brook

, et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur Urol 2019; 76: 831–842.

12.

Olaparib. In: Lexi-drugs online [database on the internet]. Hudson (OH): Lexicomp, Inc.; 2021 [updated 5 Jun 2021; cited 28 Jun 2021]. Available from: http://online.lexi.com. Subscription required to view.

13.

Rucaparib. Lexi-drugs online [database on the internet]. Hudson (OH): Lexicomp, Inc., 2021 [updated 30 Apr 2021; cited 28 Jun 2021]. Available from: http://online.lexi.com. Subscription required to view.

14.

Wellstein

Giaccone

Atkins

, et al. Pathway-Targeted therapies: monoclonal antibodies, protein kinase inhibitors, and Various small molecules. In: Brunton

Hilal-Dandan

Knollmann

(eds) Goodman & Gilman's: the pharmacological basis of therapeutics. 13e. New York, NY: McGraw-Hill Education, 2017.

15.

National Center for Biotechnology Information. PARP1 poly(ADP-ribose) polymerase 1 [Homo sapiens (human)], https://www.ncbi.nlm.nih.gov/gene/142 (2021, accessed 30 June 2021).

16.

Prasad

Horton

Wilson

. Requirements for PARP-1 covalent crosslinking to DNA (PARP-1 DPC). DNA Repair (Amst) 2020; 90: 102850.

17.

Murthy

Muggia

. PARP Inhibitors: clinical development, emerging differences, and the current therapeutic issues. Cancer Drug Resistance 2019; 2: 665–679.

18.

Lynparza (olaparib) [package insert on the internet]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2021 [revised 2021 March, cited 2021 May 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208558s019s020lbl.pdf.

19.

Rubraca (rucaparib) tablets [package insert on the internet]. Boulder (CO): Clovis Oncology, Inc. 2020 [revised May 2020; cited 2021 May 3]. Available from: https://clovisoncology.com/pdfs/RubracaUSPI.pdf.

20.

Shapiro

Kristeleit

Burris

, et al. Pharmacokinetic study of rucaparib in patients with advanced solid tumors. Clin Pharmacol Drug Dev 2019; 8: 107–118.

21.

Plummer

Swaisland

Leunen

, et al. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemother Pharmacol 2015; 76: 723–729.

22.

Liao

Watkins

Nash

, et al. Evaluation of absorption, distribution, metabolism, and excretion of [(14)C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors. Invest New Drugs 2020; 38: 765–775.

23.

Ang

Clarkson-Jones

Swaisland

, et al. 405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments. European Journal of Cancer Supplements 2010; 8: 128–129.

24.

Grechko

Skarbova

Tomaszewska-Kiecana

, et al. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment. Cancer Chemother Pharmacol 2021; 88:259–270.

25.

Xiao

Nowak

Ramlau

, et al. Evaluation of drug-drug interactions of rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp substrates in patients with an advanced solid tumor. Clin Transl Sci. 2019; 12: 58–65.

26.

Lynparza (olaparib). [Package insert on the internet]. Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2018 [revised 2018 March, cited 2021 Jun 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208558s019s020lbl.pdf.

27.

Connor

MacKenzie

DeBord

, et al. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. https://www.cdc.gov/niosh/docs/2016-161/ (2016, accessed 30 June 2021).

28.

NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings: Proposed Additions to the NIOSH Hazardous Drug List 2018, https://www.federalregister.gov/d/2018-02957 (2018, accessed 30 June 2021).

29.

AstraZeneca Access 360, https://www.lynparza.com/resources-support.html (2021, accessed 30 June 2021).

30.

Rubraca Connections, https://www.rubraca.com/ovarian-cancer/patient-support-resources/patient-savings-support-programs (2021, accessed 30 June 2021).

31.

Fong

Boss

Yap

, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123–134.

32.

Kaufman

Shapira-Frommer

Schmutzler

, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244–250.

33.

Mateo

Carreira

Sandhu

, et al. DNA-Repair Defects and olaparib in metastatic prostate cancer. N Engl J Med 2015; 373: 1697–1708.

34.

Mateo

Porta

Bianchini

, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 2020; 21: 162–174.

35.

de Bono

Mateo

Fizazi

, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med 2020; 382: 2091–2102.

36.

Abida

Patnaik

Campbell

, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol 2020; 38: 3763–3772.

37.

Abida

Campbell

Patnaik

, et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study. Clin Cancer Res 2020; 26: 2487–2496.

38.

Hussain

Mateo

Fizazi

, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med 2020; 383: 2345–2357.

39.

European Medicines Agency. Lynparza, https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza (2021, accessed 30 June 2021).

40.

European Medicines Agency. Rubraca, https://www.ema.europa.eu/en/medicines/human/EPAR/rubraca (2021, accessed 30 June 2021).

41.

Coleman

Oza

Lorusso

, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390: 1949–1961.

42.

Oza

Tinker

Oaknin

, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from study 10 and ARIEL2. Gynecol Oncol 2017; 147: 267–275.

43.

National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Antiemesis, version 1.2021, http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf (2021, accessed 30 June 2021).

44.

Tew

Lacchetti

Ellis

, et al. PARP Inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol 2020; 38: 3468–3493.

45.

Kwon DH, Booth CM, Prasad V. Untangling the PROfound trial for advanced prostate cancer: is there really a role for olaparib?. Eur Urol 2021; 79: 710–712.

46.

U.S. National Library of Medicine. Clinicaltrials.gov (2021, accessed 7 July 2021)..